SILIQ (also known by its generic name brodalumab) was approved by the FDA in February 2017 for the treatment of moderate-to-severe plaque psoriasis in adults.

SILIQ is given by injection under the skin at week 0 (the first week of treatment), week 1, and week 2, and then every 2 weeks afterwards.

To learn more, please visit the SILIQ website.